• 1
    Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005; 32: 24525.
  • 2
    Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N, et al. Gout Assessment Questionnaire: initial results of reliability, validity and responsiveness. Int J Clin Pract 2006; 60: 12107.
  • 3
    Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, et al. Evaluation of an instrument assessing influence of gout on health-related quality of life. J Rheumatol 2008; 35: 240614.
  • 4
    Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009; 48: 5826.
  • 5
    Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, et al. Health care utilization in patients with gout. Semin Arthritis Rheum 2010. E-pub ahead of print.
  • 6
    Sarkin AJ, Levack AE, Shieh MM, Kavanaugh AF, Khanna D, Singh JA, et al. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. J Eval Clin Pract 2010; 16: 12447.
  • 7
    Burnand B, Kernan WN, Feinstein AR. Indexes and boundaries for “quantitative significance” in statistical decisions. J Clin Epidemiol 1990; 43: 127384.
  • 8
    Singh JA, Taylor WJ, Simon LS, Khanna P, Stamp L, McQueen FM, et al. Patient reported outcomes in chronic gout: a report from OMERACT10. J Rheumatol 2011; 38: 14527.
  • 9
    Taylor WJ, Schumacher HJ, Baraf HS, Chapman P, Stamp L, Doherty M, et al. A modified delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 2008; 67: 88891.
  • 10
    Maroli AN, Waltrip R, Alton M, Baraf HS, Huang B, Rehrig C, et al. First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout [abstract]. Arthritis Rheum 2009; 60: S416.
  • 11
    Dalbeth N, McQueen FM, Singh JA, MacDonald PA, Edwards NL, Schumacher HR Jr, et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol 2011; 38: 145861.
  • 12
    Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Eng J Med 2005; 353: 245061.
  • 13
    Becker MA, Schumacher HR, Macdonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36: 127382.
  • 14
    Dalbeth N, Clark B, Gregory K, Gamble GD, Doyle A, McQueen FM. Computed tomography measurement of tophus volume: comparison with physical measurement. Arthritis Rheum 2007; 57: 4615.
  • 15
    Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 35660.
  • 16
    Dalbeth N, Schauer C, McDonald P, Perez-Ruiz F, Schumacher HR, et al. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Ann Rheum Dis 2011; 70: 597604.
  • 17
    Schumacher HR Jr, Becker MA, Palo WA, Streit J, Macdonald PA, Joseph-Ridge N, et al. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005; 32: 236872.
  • 18
    Schumacher HR Jr, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 15408.